Almirall has great European expectations for eczema candidate
The Spanish dermatology firm has applied for European market approval of lebrikizumab in the atopic dermatitis indication, believing that it can beat both Sanofi/Regeneron treatment Dupixent and Leo Pharma’s Adtralza.
by ulrich quistgaard, translated by daniel pedersen
Almirall’s hopes are high when it comes to atopic dermatitis treatment candidate lebrikizumab’s chances on the European market, the Spanish dermatology firm says in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Year-to date Dupixent sales surpass all of 2021
For subscribers
Leo Pharma's label extension wish granted
For subscribers
Dupixent might halt "the atopic march," research finds
For subscribers
